Starting medication for opioid addiction is a critical, vulnerable time. The standard approach requires multiple in-person visits in the first week, which can be a major barrier. A new study tested whether a telemedicine-assisted start could work just as well. In this trial with 138 adults in India, people either followed the standard in-person schedule or started with one in-person visit and then used video calls for the next five days, finishing with another in-person check.
The key finding was that the telemedicine approach was just as good at keeping people in treatment after one week. About 82% of those using telemedicine stayed, compared to about 76% with standard care—a difference that wasn't statistically significant. The study was designed to show that telemedicine wasn't meaningfully worse, and it met that goal. Side effects were similar between the two groups.
This is promising because it offers a more flexible, patient-centered path that could help more people get care, especially where travel is difficult. But there are important caveats. The study's main outcome was only measured after one week, with a follow-up at one month, so we don't know the long-term effects. It was also done at a single center with a group that was almost all men, so the results might not apply to everyone. The researchers didn't report on serious side effects or why people might have dropped out.